Australia appears to be experience potentially transformative therapy for excess weight: Retatrutide. This new dual agonist – working on both GLP-1 and GIP receptors – has promising efficacy in international research, suggesting considerable drops in BMI. While regulatory clearance hasn't occurred with the Therapeutic Goods Administration (TGA)